Allogene Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Allogene Therapeutics, Inc. (ALLO) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-12
- Allogene Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2020-06-30 was $0.00.
- Allogene Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2020-03-31 was $0.00.
- Allogene Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2019-09-30 was $33.00K.
- Allogene Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Allogene Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was $443.00K.
- Allogene Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $443.00K 10-K · filed 2026-03-12 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | |||
| 2019-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$126.00K derived: sum of 2 quarters · filed 2020-11-04 | -$176.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$209.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | -$50.00K 10-Q · filed 2020-05-06 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |